Methylene BluevsTianeptine

Methylene blue has a unique property: it acts as an alternative electron carrier in the mitochondrial electron transport chain, cycling between oxidized (blue) and reduced (leuco) forms. It can accept electrons from Complex I (NADH) and donate them directly to cytochrome c, bypassing dysfunctional Complex II and III—maintaining ATP production when mitochondria are damaged or in hypoxic conditions. Methylene blue inhibits nitric oxide synthase (NOS), reducing NO production and the formation of peroxynitrite (ONOO-), a potent oxidant that damages mitochondria. It acts as a redox cycler with antioxidant properties and may enhance cytochrome c oxidase (Complex IV) activity. At low doses, it inhibits tau protein aggregation and tau-tau interactions (relevant to Alzheimer's pathology) and may improve mitochondrial respiration through multiple mechanisms.

Tianeptine is a full agonist at mu-opioid (MOR) and delta-opioid (DOR) receptors, mediating both its antidepressant/anxiolytic effects and abuse potential at high doses. Paradoxically, it enhances serotonin reuptake via SERT—opposite to SSRIs—yet still produces antidepressant effects, possibly through opioid-mediated mood regulation. Tianeptine modulates glutamatergic signaling by reversing stress-induced downregulation of AMPA receptor subunits (GluA1/GluA2) and restoring synaptic plasticity. In the hippocampus and amygdala, it prevents stress-induced dendritic atrophy, spine loss, and CA3 pyramidal cell damage—likely through opioid receptor activation and downstream HPA axis effects. It increases BDNF levels and promotes neurogenesis. The combination of opioid agonism, glutamate normalization, and neuroplasticity enhancement underlies its unique profile.